10:01 AM EST - Angiotech Pharmaceuticals Inc. : said Thursday it has received approval from the US Food and Drug Administration to market its 5-Fluorouracil-coated central venous catheter in the United States. The device, also known as 5-FU CVC, is the first to be completely researched and developed in-house by the Vancouver company. Angiotech Pharmaceuticals Inc.
shares T.ANP are trading up 29 cents at $3.08.
